Table 1.
Baseline patient characteristics (n = 43)
| N (%) | |
|---|---|
| Median Age (years, range) | 63 (34–82) |
| Sex | |
| Male | 33 (76.7%) |
| Female | 10 (23.3%) |
| Previous gastrectomy performed with curative intent | |
| Yes | 12 (27.9%) |
| No | 31 (72.1%) |
| ECOG performance status | |
| 0 | 26 (60.5%) |
| 1 | 17 (39.5%) |
| Pathology | |
| AWD | 2 (4.7%) |
| AMD | 27 (62.8%) |
| APD | 13 (30.2%) |
| SRC | 1 (2.3%) |
| Metastasized organs | |
| Lymph node | 36 (83.7%) |
| Liver | 21 (48.8%) |
| Peritoneum | 11 (25.6%) |
| Lung | 7 (16.3%) |
| Bone | 3 (7.0%) |
| Adrenal gland | 1 (2.3%) |
| HER2 positivity | |
| IHC 3+ | 30 (69.8%) |
| IHC 2+ and SISH + | 13 (30.2%) |
| Pretreatment PD-L1 status | |
| CPS < 1 (negative) | 17 (39.5%) |
| CPS ≥ 1 (positive) | 21 (48.8%) |
| CPS ≥ 10 | 5 (11.6%) |
| Not assessed | 5 (11.6%) |
| Baseline CEAa | |
| <5 ng/mL | 15 (34.9%) |
| ≥5 ng/mL | 28 (65.1%) |
| Baseline CA 19-9a,b | |
| <34 U/mL | 19 (46.3%) |
| ≥34 U/mL | 22 (53.7%) |
| EBV positivityc | 0 (0%) |
| Deficient MMRd | 0 (0%) |
ECOG Eastern Cooperative Oncology Group; AWD adenocarcinoma well differentiated; AMD adenocarcinoma moderately differentiated; APD adenocarcinoma poorly differentiated; SRC signet ring cell; HER2 human epidermal receptor 2; IHC immunohistochemistry; SISH silver in situ hybridization; CPS combined positive score; CEA carcinoembryonic antigen; CA carbohydrate antigen; EBV Epstein–Barr virus; MMR mismatch repair.
aTumor markers are grouped by the upper limit of the normal range.
bData available for 41 of 43 patients.
cEBV positivity was determined based on EBV-encoded small RNA in in situ hybridization.
dDeficient MMR by immunohistochemistry for MLH1, MSH2, PMS2, and MSH6.